» Articles » PMID: 35267502

Non-Cancer Effects Following Ionizing Irradiation Involving the Eye and Orbit

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Mar 10
PMID 35267502
Authors
Affiliations
Soon will be listed here.
Abstract

The eye is an exemplarily challenging organ to treat when considering ocular tumors. It is at the crossroads of several major aims in oncology: tumor control, organ preservation, and functional outcomes including vision and quality of life. The proximity between the tumor and organs that are susceptible to radiation damage explain these challenges. Given a high enough dose of radiation, virtually any cancer will be destroyed with radiotherapy. Yet, the doses inevitably absorbed by normal tissues may lead to complications, the likelihood of which increases with the radiation dose and volume of normal tissues irradiated. Precision radiotherapy allows personalized decision-making algorithms based on patient and tumor characteristics by exploiting the full knowledge of the physics, radiobiology, and the modifications made to the radiotherapy equipment to adapt to the various ocular tumors. Anticipation of the spectrum and severity of radiation-induced complications is crucial to the decision of which technique to use for a given tumor. Radiation can damage the lacrimal gland, eyelashes/eyelids, cornea, lens, macula/retina, optic nerves and chiasma, each having specific dose-response characteristics. The present review is a report of non-cancer effects that may occur following ionizing irradiation involving the eye and orbit and their specific patterns of toxicity for a given radiotherapy modality.

Citing Articles

Comparison of stereotactic radiotherapy and protons for uveal melanoma patients.

Fleury E, Pignol J, Kilic E, Milder M, van Rij C, Naus N Phys Imaging Radiat Oncol. 2024; 31:100605.

PMID: 39050744 PMC: 11268348. DOI: 10.1016/j.phro.2024.100605.


Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium.

Schafer E, Rushing T, Crews K, Annesley C, Colace S, Kaiser N J Natl Cancer Inst. 2024; 116(11):1721-1729.

PMID: 38964343 PMC: 11542989. DOI: 10.1093/jnci/djae165.


Cancer and Non-Cancer Effects Following Ionizing Irradiation.

Hamada N Cancers (Basel). 2024; 16(6).

PMID: 38539476 PMC: 10969203. DOI: 10.3390/cancers16061141.


Radiation effects on retinal layers revealed by OCT, OCT-A, and perimetry as a function of dose and time from treatment.

Tamplin M, Wang J, Binkley E, Garvin M, Hyer D, Buatti J Sci Rep. 2024; 14(1):3380.

PMID: 38336828 PMC: 10858219. DOI: 10.1038/s41598-024-53830-6.


Need for a Dedicated Ophthalmic Malignancy Clinico-Biological Biobank: The Nice Ocular MAlignancy (NOMA) Biobank.

Martel A, Gastaud L, Bonnetaud C, Nahon-Esteve S, Washetine K, Bordone O Cancers (Basel). 2023; 15(8).

PMID: 37190299 PMC: 10136484. DOI: 10.3390/cancers15082372.


References
1.
Kaushik M, Pulido J, Schild S, Stafford S . Risk of radiation retinopathy in patients with orbital and ocular lymphoma. Int J Radiat Oncol Biol Phys. 2012; 84(5):1145-50. DOI: 10.1016/j.ijrobp.2011.12.097. View

2.
Kim S, Yang H, Yang S . Effects of radiation therapy on the meibomian glands and dry eye in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. BMC Ophthalmol. 2020; 20(1):24. PMC: 6958586. DOI: 10.1186/s12886-019-1301-0. View

3.
Mathis T, Levron A, Pommier P, Denis P, Thariat J, Kodjikian L . Intra- and subretinal neovascularization following radiation therapy: Contribution of OCT-angiography. J Fr Ophtalmol. 2018; 41(10):e481-e483. DOI: 10.1016/j.jfo.2018.04.007. View

4.
Meyer A, Levy C, Blondel J, DHermies F, Frau E, Schlienger P . [Optic neuropathy after proton-beam therapy for malignant choroidal melanoma]. J Fr Ophtalmol. 2000; 23(6):543-53. View

5.
Shields C, Shields J, Shields M, Augsburger J . Prevalence and mechanisms of secondary intraocular pressure elevation in eyes with intraocular tumors. Ophthalmology. 1987; 94(7):839-46. DOI: 10.1016/s0161-6420(87)33537-7. View